The DNA Medicine Institute, Inc. was awarded a $1,022,908.00 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a 5-minute point-of-care test that can rapidly measure anti-Factor Xa activity and hemoglobin levels. This diagnostic tool is intended to guide emergency management of patients on direct oral anticoagulants, potentially improving response times for critical medical interventions such as administering andexanet alfa for bleeding events or thrombolytics for acute ischemic stroke. The 2-year project grant, awarded on September 10, 2024, will leverage the company's existing microfluidic and mobile technology to create a CLIA-waivable, app-connected device capable of delivering results 10 times faster than current central lab tests. This innovation aims to provide clinicians with crucial information to inform immediate patient treatment decisions in emergent situations involving bleeding or stroke.